Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers
RCMI-PELVIS
Medico-economic Evaluation Comparing Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy: Hi Art and Dynamic Arc Therapy: RapidArc, VMAT in Cancers With Pelvic Lymph Node Irradiation: Prostate, Cervix, Anal Canal
1 other identifier
interventional
215
1 country
15
Brief Summary
The aim of the study is a medico-economic evaluation to estimate a cost differential between three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and dynamic arc therapy using two different technologies: RapidArc or VMAT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable prostate-cancer
Started Mar 2011
Longer than P75 for not_applicable prostate-cancer
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2011
CompletedFirst Submitted
Initial submission to the registry
March 28, 2011
CompletedFirst Posted
Study publicly available on registry
March 30, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2020
CompletedResults Posted
Study results publicly available
July 2, 2026
CompletedJuly 2, 2026
August 1, 2016
4.2 years
March 28, 2011
December 10, 2025
June 29, 2026
Conditions
Keywords
Study Arms (3)
Prostate
OTHERPatients with prostate cancer
Anal canal
OTHERPatients with anal canal
Cervix cancer
OTHERPatients with Cervix cancer
Interventions
IMRT using helical tomotherapy (HT) technique with prostate cancer
IMRT using Volumetric Modulated Arc Therapy (VMAT) with cervix cancer
IMRT using Dynamic arc therapy by Rapid Arc technique for patients with prostate cancer
IMRT using helical tomotherapy (HT) technique with Anal canal cancer
IMRT using helical tomotherapy (HT) technique with cervix cancer
IMRT using Volumetric Modulated Arc Therapy (VMAT) with Anal canal cancer
IMRT using Dynamic arc therapy by Rapid Arc technique for patients with Anal canal cancer
IMRT using Dynamic arc therapy by Rapid Arc technique for patients with cervix cancer
IMRT using Volumetric Modulated Arc Therapy (VMAT) with prostate cancer
Eligibility Criteria
You may qualify if:
- WHO performance index ≤ 2
- Age \> 18 years
- Histologically confirmed carcinoma
- Locally advanced anal canal cancer (\> 4 cm and/or N1 to N3), requiring irradiation of inguinal and pelvic lymph nodes with concomitant chemotherapy
- Prostate cancer requiring pelvic lymph node irradiation and hormone therapy
- Cervical cancer requiring irradiation of the pelvic lymph nodes, the primary tumor, and parametria with concomitant chemotherapy. Surgical resection may be performed after chemoradiotherapy depending on each center's practices. Boosts via external beam radiotherapy or brachytherapy are accepted
- The investigator must ensure that the patient has not expressed its opposition to participate in this study. The signing of a consent form is optional;
You may not qualify if:
- History of invasive cancer (except basal cell carcinoma)
- Indication for re-irradiation
- Lombo-aortic lymph node irradiation
- Postoperative radiotherapy
- Geographic distance likely to interfere with patient follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (15)
Hôpital Européen Georges Pompidou
Paris, Paris, 75015, France
Institut Sainte Catherine
Avignon, 84000, France
Institut Bergonié
Bordeaux, 33000, France
Centre Léon Bérard
Lyon, 69373, France
Institut Paoli Calmette
Marseille, 13273, France
Assistance publique des Hôpitaux de Marseille
Marseille, 13385, France
Hôpital Clinique Claude Bernard
Metz, 57 070, France
Groupe Oncorad
Montauban, 82000, France
Centre Val d'Aurelle
Montpellier, 34298, France
Centre Alexis Vautrin
Nancy, 54500, France
Institut Curie
Paris, 75013, France
Institut de cancérologie de l'ouest
Saint-Herblain, 44800, France
Centre Paul Strauss
Strasbourg, 67065, France
Institut Claudius Regaud
Toulouse, 31000, France
Groupe Oncorad
Toulouse, 31300, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stéphane SUPIOT, MD, PhD
Institut de Cancérologie de l'Ouest
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 28, 2011
First Posted
March 30, 2011
Study Start
March 1, 2011
Primary Completion
May 1, 2015
Study Completion
February 1, 2020
Last Updated
July 2, 2026
Results First Posted
July 2, 2026
Record last verified: 2016-08